Ascendis Pharma A/S (ASND) News Today $152.43 -2.15 (-1.39%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$152.51 +0.08 (+0.05%) As of 02/21/2025 05:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period New York State Common Retirement Fund Acquires 25,164 Shares of Ascendis Pharma A/S (NASDAQ:ASND)New York State Common Retirement Fund boosted its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 14.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 204,482 shares of the biotechnology company's stock aFebruary 21 at 4:19 AM | marketbeat.comEvercore ISI Forecasts Strong Price Appreciation for Ascendis Pharma A/S (NASDAQ:ASND) StockFebruary 20 at 1:43 AM | americanbankingnews.comAscendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $260.00 at Evercore ISIEvercore ISI upped their price objective on Ascendis Pharma A/S from $220.00 to $260.00 and gave the company an "outperform" rating in a research note on Tuesday.February 19 at 10:46 AM | marketbeat.comAscendis Pharma price target raised to $180 from $175 at Morgan StanleyFebruary 18, 2025 | markets.businessinsider.comRice Hall James & Associates LLC Has $22.56 Million Stock Holdings in Ascendis Pharma A/S (NASDAQ:ASND)Rice Hall James & Associates LLC raised its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 2.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 163,888 shares of the biotechnologFebruary 18, 2025 | marketbeat.comLeerink Partnrs Issues Optimistic Forecast for ASND EarningsFebruary 18, 2025 | americanbankingnews.comEquities Analysts Offer Predictions for ASND Q1 EarningsFebruary 17, 2025 | americanbankingnews.comLeerink Partnrs Issues Optimistic Outlook for ASND EarningsAscendis Pharma A/S (NASDAQ:ASND - Free Report) - Research analysts at Leerink Partnrs lifted their Q1 2025 EPS estimates for Ascendis Pharma A/S in a research report issued to clients and investors on Wednesday, February 12th. Leerink Partnrs analyst J. Schwartz now forecasts that the biotechnolFebruary 17, 2025 | marketbeat.comQ1 EPS Estimates for Ascendis Pharma A/S Lowered by WedbushAscendis Pharma A/S (NASDAQ:ASND - Free Report) - Stock analysts at Wedbush reduced their Q1 2025 earnings per share estimates for Ascendis Pharma A/S in a research report issued on Wednesday, February 12th. Wedbush analyst Y. Zhong now anticipates that the biotechnology company will post earningFebruary 17, 2025 | marketbeat.comAllspring Global Investments Holdings LLC Trims Stock Position in Ascendis Pharma A/S (NASDAQ:ASND)Allspring Global Investments Holdings LLC decreased its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 5.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 152,738 shares of the biotechnologFebruary 16, 2025 | marketbeat.comJPMorgan Chase & Co. Increases Ascendis Pharma A/S (NASDAQ:ASND) Price Target to $168.00February 16, 2025 | americanbankingnews.comWhat is Wedbush's Forecast for ASND FY2029 Earnings?Ascendis Pharma A/S (NASDAQ:ASND - Free Report) - Wedbush lifted their FY2029 earnings per share estimates for shares of Ascendis Pharma A/S in a report released on Wednesday, February 12th. Wedbush analyst Y. Zhong now forecasts that the biotechnology company will earn $14.13 per share for the yFebruary 15, 2025 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?February 15, 2025 | finance.yahoo.comThe Goldman Sachs Group Forecasts Strong Price Appreciation for Ascendis Pharma A/S (NASDAQ:ASND) StockFebruary 15, 2025 | americanbankingnews.comAscendis Pharma A/S (NASDAQ:ASND) Shares Gap Up on Strong EarningsFebruary 15, 2025 | americanbankingnews.comQ4 2024 Ascendis Pharma A/S Earnings Call TranscriptFebruary 13, 2025 | gurufocus.comAscendis Pharma A/S Earnings Call Highlights Growth and ChallengesFebruary 13, 2025 | tipranks.comAscendis Pharma price target lowered to $192 from $203 at BofAFebruary 13, 2025 | markets.businessinsider.comAscendis Pharma price target raised to $162 from $153 at TD CowenFebruary 13, 2025 | markets.businessinsider.comAscendis Pharma (ASND) Receives a Buy from J.P. MorganFebruary 13, 2025 | markets.businessinsider.comAscendis Pharma A/S (NASDAQ:ASND) Q4 2024 Earnings Call TranscriptFebruary 13, 2025 | msn.comAscendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $225.00 at The Goldman Sachs GroupThe Goldman Sachs Group upped their price target on Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a "buy" rating in a research report on Thursday.February 13, 2025 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Given New $168.00 Price Target at JPMorgan Chase & Co.JPMorgan Chase & Co. boosted their price objective on shares of Ascendis Pharma A/S from $167.00 to $168.00 and gave the stock an "overweight" rating in a research report on Thursday.February 13, 2025 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Shares Gap Up on Better-Than-Expected EarningsAscendis Pharma A/S (NASDAQ:ASND) Shares Gap Up on Strong EarningsFebruary 13, 2025 | marketbeat.comAscendis Pharma targets €200M SKYTROFA revenue and expands YORVIPATH globally in 2025February 13, 2025 | seekingalpha.comAscendis Pharma A/S (ASND) Q4 2024 Earnings Call TranscriptFebruary 13, 2025 | seekingalpha.comAscendis Pharma announces share repurchase program, settlement of certain RSUsFebruary 12, 2025 | markets.businessinsider.comAscendis Pharma reports Q4 EPS (EUR 0.64) vs (EUR 1.53) last yearFebruary 12, 2025 | markets.businessinsider.comEarnings call transcript: Ascendis Pharma Q4 2024 sees revenue riseFebruary 12, 2025 | msn.comAscendis Pharma launches $25 million share buybackFebruary 12, 2025 | msn.comAscendis Pharma A/S (NASDAQ:ASND) Posts Earnings Results, Beats Estimates By $0.64 EPSAscendis Pharma A/S (NASDAQ:ASND - Get Free Report) announced its quarterly earnings data on Wednesday. The biotechnology company reported ($0.68) EPS for the quarter, topping analysts' consensus estimates of ($1.32) by $0.64.February 12, 2025 | marketbeat.comAscendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUsFebruary 12, 2025 | globenewswire.comAscendis Pharma Reports Fourth Quarter and Full Year 2024 Financial ResultsFebruary 12, 2025 | globenewswire.comCantor Fitzgerald Reiterates "Overweight" Rating for Ascendis Pharma A/S (NASDAQ:ASND)February 12, 2025 | americanbankingnews.comAscendis Pharma A/S (NASDAQ:ASND) Given "Overweight" Rating at Cantor FitzgeraldCantor Fitzgerald reaffirmed an "overweight" rating and issued a $170.00 target price on shares of Ascendis Pharma A/S in a research note on Tuesday.February 11, 2025 | marketbeat.comMorgan Stanley Remains a Hold on Ascendis Pharma (ASND)February 10, 2025 | markets.businessinsider.comabrdn plc Buys 28,967 Shares of Ascendis Pharma A/S (NASDAQ:ASND)abrdn plc grew its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 18.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 187,180 shares of the biotechnology company's stock after acquFebruary 6, 2025 | marketbeat.comAscendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025February 5, 2025 | globenewswire.comMatisse Capital Has $4.20 Million Position in Ascendis Pharma A/S (NASDAQ:ASND)Matisse Capital reduced its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 9.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 30,496 shares of the biotechnology company's stock after selling 3,188 shares during thFebruary 4, 2025 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Given Average Rating of "Moderate Buy" by AnalystsAscendis Pharma A/S (NASDAQ:ASND - Get Free Report) has been given an average rating of "Moderate Buy" by the fourteen research firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and thirteen have asFebruary 3, 2025 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Sees Significant Decrease in Short InterestAscendis Pharma A/S (NASDAQ:ASND - Get Free Report) saw a significant drop in short interest in the month of January. As of January 15th, there was short interest totalling 3,420,000 shares, a drop of 5.5% from the December 31st total of 3,620,000 shares. Based on an average daily volume of 426,500 shares, the short-interest ratio is presently 8.0 days.February 2, 2025 | marketbeat.comJ.P. Morgan Sticks to Their Buy Rating for Ascendis Pharma (ASND)January 29, 2025 | markets.businessinsider.comJPMorgan raises Ascendis Pharma target to $167, keeps OverweightJanuary 29, 2025 | msn.comAscendis-Novo Weight Loss Deal Highlights Technology Platform, Signals Growth Potential (Rating Upgrade)January 29, 2025 | seekingalpha.comAscendis Pharma A/S (NASDAQ:ASND) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst SaysJPMorgan Chase & Co. increased their target price on Ascendis Pharma A/S from $165.00 to $167.00 and gave the company an "overweight" rating in a report on Wednesday.January 29, 2025 | marketbeat.comAscendis Pharma A/S (ASND) Expected to Announce Earnings on WednesdayAscendis Pharma A/S (NASDAQ:ASND) will be releasing earnings before the market opens on Wednesday, February 5, Financial Modeling Prep reports.January 29, 2025 | marketbeat.comAscendis Pharma: Danish Blockbuster HunterJanuary 29, 2025 | seekingalpha.comSG Americas Securities LLC Grows Stock Holdings in Ascendis Pharma A/S (NASDAQ:ASND)SG Americas Securities LLC grew its position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 410.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 33,944 shares of the biotechnology company's stock after puJanuary 25, 2025 | marketbeat.comCrossmark Global Holdings Inc. Boosts Stake in Ascendis Pharma A/S (NASDAQ:ASND)Crossmark Global Holdings Inc. raised its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 28.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,435 shares of the biotechnology company's stJanuary 25, 2025 | marketbeat.comStrong Buy Recommendation for Ascendis Pharma Driven by Yorvipath’s Market Potential and Clinical EfficacyJanuary 24, 2025 | markets.businessinsider.com Get Ascendis Pharma A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter. Email Address ASND Media Mentions By Week ASND Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ASND News Sentiment▼0.730.60▲Average Medical News Sentiment ASND News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ASND Articles This Week▼196▲ASND Articles Average Week Get Ascendis Pharma A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BNTX News Today TEVA News Today SMMT News Today GMAB News Today ITCI News Today VTRS News Today MRNA News Today RDY News Today PCVX News Today SRPT News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ASND) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | Sponsored$5,000 DOGE check?Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a porti...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredEx-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. ...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored2025 AI Blueprint features Nvidia’s march to $5 trillionNvidia is now one of the most valuable companies in the world. It currently ranks second, just behind Apple...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascendis Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascendis Pharma A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
